ID: ALA379849

Max Phase: Preclinical

Molecular Formula: C19H15F2NO

Molecular Weight: 311.33

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1/C(=C/c2ccccc2F)CNC/C1=C\c1ccccc1F

Standard InChI:  InChI=1S/C19H15F2NO/c20-17-7-3-1-5-13(17)9-15-11-22-12-16(19(15)23)10-14-6-2-4-8-18(14)21/h1-10,22H,11-12H2/b15-9+,16-10+

Standard InChI Key:  NIVYQYSNRUIFIF-KAVGSWPWSA-N

Associated Targets(Human)

RPMI-7951 420 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A2780 11979 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A549 127892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-435 38290 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NCI-H441 233 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MCF7 126967 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MAP kinase-activated protein kinase 2 4814 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MAP kinase p38 alpha 12866 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vascular endothelial growth factor receptor 2 20924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase Nek1 1886 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MAP kinase ERK2 25055 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Dual specificity mitogen-activated protein kinase kinase 1 4127 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase RAF 4169 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

AMP-activated protein kinase (AMPK) alpha-1/beta-1/gamma-1 619 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Ribosomal protein S6 kinase 1 4456 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Inhibitor of nuclear factor kappa B kinase beta subunit 5554 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase AKT2 4301 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase AKT 9192 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Caco-2 12174 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NCI-H1650 1118 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

518A2 464 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HT-29 80576 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HCT-116 91556 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

DLD-1 17511 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PANC-1 6144 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HeLa 229 50 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

SGC-7901 2773 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MGC-803 6426 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NCI-H460 60772 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NCI-H1975 4994 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

L02 4864 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

U-251 51189 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HepG2 196354 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

QGY-7703 248 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

SMMC-7721 5516 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HEK293 82097 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

CHO 4503 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

H9c2 3506 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RAW264.7 28094 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDCK 10148 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mycobacterium tuberculosis 203094 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mycobacterium marinum 465 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Lewis lung carcinoma cell line 1243 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Danio rerio 3092 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Gallus gallus 1187 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Trypanosoma brucei 78846 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 311.33Molecular Weight (Monoisotopic): 311.1122AlogP: 3.60#Rotatable Bonds: 2
Polar Surface Area: 29.10Molecular Species: NEUTRALHBA: 2HBD: 1
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.29CX LogP: 4.18CX LogD: 4.15
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.86Np Likeness Score: -0.60

References

1. Sun A, Shoji M, Lu YJ, Liotta DC, Snyder JP..  (2006)  Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system.,  49  (11): [PMID:16722634] [10.1021/jm051141k]
2. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P..  (2007)  EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.,  282  (39): [PMID:17684018] [10.1074/jbc.m703796200]
3. Sun A, Lu YJ, Hu H, Shoji M, Liotta DC, Snyder JP..  (2009)  Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism.,  19  (23): [PMID:19854644] [10.1016/j.bmcl.2009.10.023]
4. Lagisetty P, Vilekar P, Sahoo K, Anant S, Awasthi V..  (2010)  CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones.,  18  (16): [PMID:20638855] [10.1016/j.bmc.2010.06.055]
5. Kálai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, Hideg K..  (2011)  Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity.,  54  (15): [PMID:21702507] [10.1021/jm200353f]
6. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP..  (2013)  Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.,  56  (9): [PMID:23550937] [10.1021/jm4002692]
7. Wu J, Zhang Y, Cai Y, Wang J, Weng B, Tang Q, Chen X, Pan Z, Liang G, Yang S..  (2013)  Discovery and evaluation of piperid-4-one-containing mono-carbonyl analogs of curcumin as anti-inflammatory agents.,  21  (11): [PMID:23611769] [10.1016/j.bmc.2013.03.057]
8. Moore TW, Zhu S, Randolph R, Shoji M, Snyder JP..  (2014)  Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109.,  (4): [PMID:24900828] [10.1021/ml4002453]
9. Tan KL, Ali A, Du Y, Fu H, Jin HX, Chin TM, Khan M, Go ML..  (2014)  Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells.,  57  (14): [PMID:24960549] [10.1021/jm401352a]
10. Singh RS, Michel D, Das U, Dimmock JR, Alcorn J..  (2014)  Cytotoxic 1,5-diaryl-3-oxo-1,5-pentadienes: an assessment and comparison of membrane permeability using Caco-2 and MDCK monolayers.,  24  (22): [PMID:25442312] [10.1016/j.bmcl.2014.09.074]
11. Baldwin PR, Reeves AZ, Powell KR, Napier RJ, Swimm AI, Sun A, Giesler K, Bommarius B, Shinnick TM, Snyder JP, Liotta DC, Kalman D..  (2015)  Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.,  92  [PMID:25618016] [10.1016/j.ejmech.2015.01.020]
12. Wu J, Wu S, Shi L, Zhang S, Ren J, Yao S, Yun D, Huang L, Wang J, Li W, Wu X, Qiu P, Liang G..  (2017)  Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anti-cancer agents for lung cancer.,  125  [PMID:27886548] [10.1016/j.ejmech.2016.10.027]
13. Schmitt F, Gold M, Begemann G, Andronache I, Biersack B, Schobert R..  (2017)  Fluoro and pentafluorothio analogs of the antitumoral curcuminoid EF24 with superior antiangiogenic and vascular-disruptive effects.,  25  (17): [PMID:28774574] [10.1016/j.bmc.2017.07.039]
14. Jin R, Chen Q, Yao S, Bai E, Fu W, Wang L, Wang J, Du X, Wei T, Xu H, Jiang C, Qiu P, Wu J, Li W, Liang G..  (2018)  Synthesis and anti-tumor activity of EF24 analogues as IKKβ inhibitors.,  144  [PMID:29351887] [10.1016/j.ejmech.2017.11.077]
15. Chen L, Li Q, Weng B, Wang J, Zhou Y, Cheng D, Sirirak T, Qiu P, Wu J..  (2018)  Design, synthesis, anti-lung cancer activity, and chemosensitization of tumor-selective MCACs based on ROS-mediated JNK pathway activation and NF-κB pathway inhibition.,  151  [PMID:29655083] [10.1016/j.ejmech.2018.03.051]
16. Zhu M, Wang J, Xie J, Chen L, Wei X, Jiang X, Bao M, Qiu Y, Chen Q, Li W, Jiang C, Zhou X, Jiang L, Qiu P, Wu J..  (2018)  Design, synthesis, and evaluation of chalcone analogues incorporate α,β-Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis.,  157  [PMID:30196062] [10.1016/j.ejmech.2018.08.072]
17. Zhao S, Pi C, Ye Y, Zhao L, Wei Y..  (2019)  Recent advances of analogues of curcumin for treatment of cancer.,  180  [PMID:31336310] [10.1016/j.ejmech.2019.07.034]
18. Yao BR, Sun Y, Chen SL, Suo HD, Zhang YL, Wei H, Wang CH, Zhao F, Cong W, Xin WY, Hou GG..  (2019)  Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation.,  167  [PMID:30771605] [10.1016/j.ejmech.2019.02.020]
19. Francisco KR, Monti L, Yang W, Park H, Liu LJ, Watkins K, Amarasinghe DK, Nalli M, Roberto Polaquini C, Regasini LO, Eduardo Miller Crotti A, Silvestri R, Guidi Magalhães L, Caffrey CR..  (2023)  Structure-activity relationship of dibenzylideneacetone analogs against the neglected disease pathogen, Trypanosoma brucei.,  81  [PMID:36608774] [10.1016/j.bmcl.2023.129123]

Source